Antigenic mapping reveals sites of vulnerability on α-HCoV spike protein

Commun Biol. 2022 Nov 4;5(1):1179. doi: 10.1038/s42003-022-04160-8.

Abstract

Understanding the antigenic signatures of all human coronaviruses (HCoVs) Spike (S) proteins is imperative for pan-HCoV epitopes identification and broadly effective vaccine development. To depict the currently elusive antigenic signatures of α-HCoVs S proteins, we isolated a panel of antibodies against the HCoV-229E S protein and characterized their epitopes and neutralizing potential. We found that the N-terminal domain of HCoV-229E S protein is antigenically dominant wherein an antigenic supersite is present and appears conserved in HCoV-NL63, which holds potential to serve as a pan-α-HCoVs epitope. In the receptor binding domain, a neutralizing epitope is captured in the end distal to the receptor binding site, reminiscent of the locations of the SARS-CoV-2 RBD cryptic epitopes. We also identified a neutralizing antibody that recognizes the connector domain, thus representing the first S2-directed neutralizing antibody against α-HCoVs. The unraveled HCoVs S proteins antigenic similarities and variances among genera highlight the challenges faced by pan-HCoV vaccine design while supporting the feasibility of broadly effective vaccine development against a subset of HCoVs.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antibodies, Neutralizing
  • Antigens, Viral
  • COVID-19*
  • Coronavirus 229E, Human*
  • Epitopes
  • Humans
  • SARS-CoV-2
  • Spike Glycoprotein, Coronavirus / genetics

Substances

  • spike protein, SARS-CoV-2
  • Spike Glycoprotein, Coronavirus
  • Antigens, Viral
  • Epitopes
  • Antibodies, Neutralizing